AstraZeneca: Advantage for BioNTech

BioNTech and its partner Pfizer are hoping that their corona vaccine will be approved for the market soon. Moderna is also in the starting blocks. AstraZeneca, on the other hand, is lagging behind. After complications, the phase II / III study of your own vaccine is continued together with Oxford University. However, the competitors have a clear time advantage. The AstraZeneca vaccine may therefore have to have special characteristics in order to compete in the market.

The analysts at Independent Research expect the company to have earnings per share of $ 2.22 in 2020 (old: $ 2.31). The estimate for 2021 drops from $ 3.29 to $ 3.23.

They continue to give a hold recommendation for the shares of AstraZeneca. The price target drops from GBp 8,900.00 to GBp 8,600.00.

AstraZeneca’s latest quarterly figures slightly missed expectations. Sales rose 2.7 percent to $ 6.578 billion in the third quarter. The analyst’s model was $ 6.72 billion. Adjusted EBIT dropped from $ 1.9 billion to $ 1.8 billion.


Related Articles

Back to top button